Skip to main content

Drug Interactions between vorasidenib and Xarelto

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

rivaroxaban vorasidenib

Applies to: Xarelto (rivaroxaban) and vorasidenib

Theoretically, coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of rivaroxaban, which is a substrate of the isoenzyme as well as the efflux transporter. In a pharmacokinetic study, administration of a single 20 mg dose of rivaroxaban with the potent CYP450 3A4 and P-gp inducer rifampin (titrated up to 600 mg once daily) resulted in approximately 22% and 50% decreases in mean rivaroxaban peak plasma concentration (Cmax) and system exposure (AUC), respectively, with parallel decreases in its pharmacodynamic effects. The effects of less potent inducers of either CYP450 3A4 or P-gp have not been studied.

References (6)
  1. (2023) "Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals, SUPPL-41
  2. (2023) "Product Information. Xarelto (rivaroxaban)." Bayer Plc
  3. (2025) "Product Information. Rivaroxaban (rivaroxaban)." Lupin Pharmaceuticals Inc
  4. (2024) "Product Information. Rivaroxaban (rivaroxaban)." Amarox Ltd
  5. (2024) "Product Information. Xarelto (rivaroxaban)." Bayer Australia Limited
  6. (2025) "Product Information. Ag-Rivaroxaban (rivaroxaban)." Angita Pharma Inc.

Drug and food interactions

Moderate

vorasidenib food

Applies to: vorasidenib

GENERALLY AVOID: Due to induction of CYP450 1A2, the isoenzyme primarily responsible for the metabolic clearance of vorasidenib, smoking tobacco during treatment with vorasidenib may decrease its plasma concentrations and anti-tumor effect. Clinical and pharmacokinetic data are currently lacking.

MANAGEMENT: Patient should be advised to avoid smoking tobacco during treatment with vorasidenib because it may reduce efficacy of the therapy.

References (1)
  1. (2024) "Product Information. Voranigo (vorasidenib)." Servier Pharmaceuticals LLC

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer